Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107643 | 0.85 | ALOX5 (0.39) | SLC6A2SLC6A4SLC6A3TAAR1SLC7A5 | |
| SCHEMBL439568 | 0.85 | TAS1R3 (0.36) | SLC6A2SLC6A4SLC6A3ALOX5NPC1 | |
| SCHEMBL2880798 | 0.84 | ALOX5 (0.39) | SLC6A2SLC6A4SLC6A3ALOX5NPC1 | |
| SCHEMBL9880970 | 0.84 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3TAAR1SLC7A5 | |
| SCHEMBL17787300 | 0.81 | ALOX5 (0.37) | SLC6A2SLC6A4SLC6A3ALOX5NPC1 | |
| SCHEMBL2887376 | 0.81 | KDM4E (0.44) | ALOX5NPC1RAB9AKMT2ACES2 | |
| SCHEMBL598926 | 0.80 | KDM4E (0.40) | SLC7A5ALOX5NPC1RAB9AKMT2A | |
| SCHEMBL1422000 | 0.79 | NR1I2 (0.42) | SLC7A5L3MBTL1 | |
| SCHEMBL2494816 | 0.79 | NR1I2 (0.42) | SLC7A5L3MBTL1 | |
| SCHEMBL2888749 | 0.79 | NR1I2 (0.42) | SLC7A5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.